IRAN DIABETES CARE DEVICES MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

IRAN DIABETES CARE DEVICES MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

Iran Diabetes Care Devices Market is expected to register a CAGR greater than 5% over the forecast period, 2022-2027.

The most significant challenges of diabetes care management in developing countries during the COVID-19 pandemic include inadequate preventive measures, interrupted traditional methods of relationship with the patient, medication shortages, disruption of routine diabetic care, and a lack of the necessary infrastructure for telehealth services. Diabetes prevalence is increasing in Iran, as it is in many other nations. In addition to the problems inherent with diabetes management in impoverished nations, Iran has encountered new hurdles in the last two years as sanctions have tightened. During the COVID-19 crisis in Iran, the weight of sanctions more than quadrupled.

The most important components of diabetes self-management that should be considered to better control hyperglycemia and prevent or at least delay complications in diabetic patients are regular blood glucose monitoring, following a healthy diet, regular physical activity, and compliance with medication and foot care. Shortages or the high prices of devices such as insulin pens escalated the anxiety of patients with diabetes and complicated the management of their disease during the COVID-19 crisis.

Key Market TrendsManagement Devices Hold Highest Market Share in Iran Diabetes Care Devices Market

Type 1 diabetes (T1D) patients must maintain good lifestyle conditions, which are influenced by a person's personality qualities, social interactions, socioeconomic situations, and environmental living variables. Continuous glucose monitoring (CGM) combined with multiple daily injections (MDI) has been demonstrated to reduce nonsevere and severe hypoglycemia in persons with T1D who are prone to this side event. Patients with T1D who are at high risk of hypoglycemia can employ standalone continuous glucose monitoring to regulate their blood sugar levels even in the terrible living conditions imposed by the COVID-19 pandemic crisis's draconian lockdown.

Diabetes patients in Iran face financial hardship. Pharmacies do not sell enough insulin to diabetics; instead, insulin is sold at a higher price on the open market. Sometimes the parent of a diabetic child is unable to locate insulin. Insulin costs 20-30% of a family's monthly income for children and adults with type 1 diabetes. This does not include the cost of test strips and other supplies, which are extremely costly. Furthermore, insurance companies in Iran are reducing financial support for diabetic treatments. The availability of insulin is restricted, and Iranian families with diabetic children cope by reducing the number of carbohydrates in their child's diet.

Despite all these in Iran usage of Insulin management devices increasing over the years

Increasing Type -1 Diabetes Population in Iran

Diabetes is a serious public health concern in Iran, the Middle East's second-largest country, due to its high prevalence rate, growing occurrence rate, and economic impact. It is estimated that by the year 2030, 9.2 million Iranian individuals will have diabetes. Diabetes-related mortality in Iran continues to rise; the age-standardized death rate from diabetes has risen throughout the years. Diabetes has significant economic consequences in the country. Diabetes, in addition to its high direct health-care costs, is a significant risk factor for other chronic illnesses such as cardiovascular disease. Diabetes complications, for example, accounted for USD 412 (49%) of the USD 843 per capita cost of diabetes. Yazd, a world heritage city located in the center of Iran, has one of the highest recorded prevalences of DM in Iran. Other cities in Iran have varying levels of DM awareness. For example, in Kerman, a province south of Yazd, the prevalence of undiagnosed diabetes is only 2.7%, but it is 25% in northern Iran.

Despite the widespread availability of drugs and insulin coverage in Iran, the estimated national control of hyperglycemia, hyperlipidemia, and hypertension (particularly among young men and women) remains inadequate.

As a result, Iran's diabetes care devices market is predicted to expand gradually in the coming years.

Competitive Landscape

The new technologies in diabetes devices, like continuous glucose monitoring, increased the market for monitoring devices. The mergers and acquisitions between the players, like the acquisition of TypeZero Technologies by Dexcom, are paving the way for automated insulin delivery. The acquisition has sent Dexcom ahead on its way in the race to create an artificial pancreas system, rather than merely offering a boost to the continuous glucose monitoring devices market.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.